Cardiff Oncology, Inc. reported a net loss of $13.434 million for the first quarter of 2025, compared to a net loss of $10.011 million for the same period in 2024. Total revenues decreased to $0.109 million from $0.205 million year-over-year. The company's cash and cash equivalents stood at $24.095 million as of March 31, 2025, down from $51.470 million at the end of 2024. Operating expenses increased significantly, driven by higher research and development costs.

Cardiff Oncology announced positive initial data from its ongoing first-line RAS-mutated mCRC clinical trial (CRDF-004), with a 64% objective response rate in the 30mg onvansertib dose arm. The company also raised $40 million in an oversubscribed offering, strengthening its cash position to $91.7 million, projected to fund operations into Q1 2027.

Cardiff Oncology reported its third quarter 2024 financial results, highlighting the publication of positive Phase 2 trial results in the Journal of Clinical Oncology and the expected initial data readout from the first-line RAS-mutated mCRC randomized CRDF-004 trial by the end of 2024. The company's cash resources are projected to fund operations into Q1 2026.

Cardiff Oncology reported $60.3 million in cash and cash equivalents as of June 30, 2024. The company's operating expenses were $12.7 million for the quarter, with a net loss of $11.8 million, or $0.26 per share. They believe that current cash resources are sufficient to fund operations through the end of Q3 2025.

Cardiff Oncology reported cash and equivalents of $67.2 million as of March 31, 2024, with a projected runway into Q3 2025. The company's net cash used in operating activities for the first quarter of 2024 was approximately $7.7 million. They also presented updated data at AACR Annual Meeting 2024 that supports ongoing first-line RAS-mutated mCRC clinical study.

Cardiff Oncology reported having $75 million in cash and cash equivalents as of December 31, 2023, sufficient to fund operations into Q3 2025. The company's operating expenses increased to $45.9 million for the full year ended December 31, 2023. First patient was dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC.

Cardiff Oncology reported $81.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023. The company's lead program in RAS-mutated mCRC is advancing to the first-line setting based on positive data and FDA guidance. An expanded relationship with Pfizer will support a new Phase 2 trial.

Cardiff Oncology reported $89.4 million in cash, cash equivalents, and short-term investments as of June 30, 2023. The company's lead program advanced to the first-line mCRC setting, and its relationship with Pfizer expanded.

Cardiff Oncology reported its first-quarter 2023 results, highlighting the dosing of the first patient in the Phase 2 ONSEMBLE trial and the appointment of Fairooz Kabbinavar as Chief Medical Officer. The company's cash, cash equivalents, and short-term investments totaled approximately $97 million as of March 31, 2023, which is projected to fund operations into 2025.

Cardiff Oncology reported continued progress in their Phase 1b/2 trial for KRAS-mutated mCRC, demonstrating promising objective response rates and progression-free survival. They strengthened their leadership team and anticipate multiple data readouts from clinical programs and IITs in 2023. The company's strong cash position is expected to fund operations into 2025.

Cardiff Oncology announced Phase 1b/2 data demonstrating onvansertib's ability to generate durable responses in KRAS-mutated mCRC patients. The company plans to activate ONSEMBLE, a randomized Phase 2 trial in Q4 2022. Cardiff Oncology had approximately $114 million in cash, cash equivalents, and short-term investments as of September 30, 2022, providing projected runway into 2025.

Cardiff Oncology reported its second quarter 2022 financial results, highlighting preclinical data in ovarian cancer and data from its Phase 2 metastatic castration-resistant prostate cancer clinical trial. The company had approximately $122 million in cash, cash equivalents, and short-term investments as of June 30, 2022.

Cardiff Oncology reported new Phase 1b/2 data from its lead KRAS-mutated metastatic colorectal cancer clinical program, showing objective response rate and median progression-free survival that substantially exceed those recorded in historical control trials. As of March 31, 2022, Cardiff Oncology had approximately $129.4 million in cash, cash equivalents, and short-term investments.

Cardiff Oncology reported fourth-quarter and full-year 2021 results, highlighting continued progress in its lead KRAS-mutated metastatic colorectal cancer program, a $15 million equity investment from Pfizer, and strategic leadership appointments. The company's cash, cash equivalents, and short-term investments totaled approximately $141 million as of December 31, 2021.

Cardiff Oncology reported third quarter results, highlighting positive clinical data from its KRAS-mutated metastatic colorectal cancer program and the appointments of a new CMO and CFO. The company had $134 million in cash, cash equivalents, and short-term investments as of September 30, 2021. Total operating expenses were $7.1 million for the quarter, with increases in research and development, and selling, general and administrative expenses.

Cardiff Oncology reported its second quarter 2021 results, highlighting advancements in its clinical programs, particularly in KRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company's leadership was strengthened with new appointments, and the financial results indicated a strong cash position of approximately $140 million.

Cardiff Oncology reported $125.6 million in cash, cash equivalents and short-term investments as of March 31, 2021. Total operating expenses were $5.5 million for the quarter, with a net loss attributable to common stockholders of $5.185 million, or $0.14 per share.

Cardiff Oncology announced positive results for Q4 2020, marked by key clinical milestones and a successful $100 million capital raise. The company is advancing its clinical programs, particularly in KRAS-mutated cancers, and expanding its pipeline.

Cardiff Oncology reported its second quarter 2020 results, highlighting clinical advancements in KRAS-mutated metastatic colorectal cancer and acute myeloid leukemia programs, along with securing $25.1 million in equity investments, warrant exercises, and clinical trial funding commitments.

Trovagene, Inc., soon to be Cardiff Oncology, reported its first quarter 2020 financial results, with total operating expenses of approximately $4.2 million and a net loss of $4.089 million. The company highlighted promising data from its ongoing clinical trials of onvansertib and announced a company name change and leadership transition.